Clinical trial
To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV…
NCT00345956 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00345956 |
|---|---|
| Title | To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam) |
| Official title | A Placebo-controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine, When Given to Healthy Infants, in Vietnam |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | Human rotavirus liquid vaccine |
| Enrollment | 375 |
| Start date | Sep 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Jun 29, 2006 |
| Last update posted | Oct 28, 2016 |
| Countries | Vietnam |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: